Literature DB >> 23623501

A Vibrio parahaemolyticus T3SS effector mediates pathogenesis by independently enabling intestinal colonization and inhibiting TAK1 activation.

Xiaohui Zhou1, Benjamin E Gewurz, Jennifer M Ritchie, Kaoru Takasaki, Hannah Greenfeld, Elliott Kieff, Brigid M Davis, Matthew K Waldor.   

Abstract

Vibrio parahaemolyticus type III secretion system 2 (T3SS2) is essential for the organism's virulence, but the effectors required for intestinal colonization and induction of diarrhea by this pathogen have not been identified. Here, we identify a type III secretion system (T3SS2)-secreted effector, VopZ, that is essential for V. parahaemolyticus pathogenicity. VopZ plays distinct, genetically separable roles in enabling intestinal colonization and diarrheagenesis. Truncation of VopZ prevents V. parahaemolyticus colonization, whereas deletion of VopZ amino acids 38-62 abrogates V. parahaemolyticus-induced diarrhea and intestinal pathology but does not impair colonization. VopZ inhibits activation of the kinase TAK1 and thereby prevents the activation of MAPK and NF-κB signaling pathways, which lie downstream. In contrast, the VopZ internal deletion mutant cannot counter the activation of pathways regulated by TAK1. Collectively, our findings suggest that VopZ's inhibition of TAK1 is critical for V. parahaemolyticus to induce diarrhea and intestinal pathology.
Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23623501      PMCID: PMC3711673          DOI: 10.1016/j.celrep.2013.03.039

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  52 in total

1.  Genome sequence of Vibrio parahaemolyticus: a pathogenic mechanism distinct from that of V cholerae.

Authors:  Kozo Makino; Kenshiro Oshima; Ken Kurokawa; Katsushi Yokoyama; Takayuki Uda; Kenichi Tagomori; Yoshio Iijima; Masatomo Najima; Masayuki Nakano; Atsushi Yamashita; Yoshino Kubota; Shigenobu Kimura; Teruo Yasunaga; Takeshi Honda; Hideo Shinagawa; Masahira Hattori; Tetsuya Iida
Journal:  Lancet       Date:  2003-03-01       Impact factor: 79.321

2.  Enterohemorrhagic Escherichia coli O157:H7 produces Tir, which is translocated to the host cell membrane but is not tyrosine phosphorylated.

Authors:  R DeVinney; M Stein; D Reinscheid; A Abe; S Ruschkowski; B B Finlay
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  TAK1 mitogen-activated protein kinase kinase kinase is activated by autophosphorylation within its activation loop.

Authors:  K Kishimoto; K Matsumoto; J Ninomiya-Tsuji
Journal:  J Biol Chem       Date:  2000-03-10       Impact factor: 5.157

4.  Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation.

Authors:  Sohini Mukherjee; Gladys Keitany; Yan Li; Yong Wang; Haydn L Ball; Elizabeth J Goldsmith; Kim Orth
Journal:  Science       Date:  2006-05-26       Impact factor: 47.728

5.  Serine/threonine acetylation of TGFβ-activated kinase (TAK1) by Yersinia pestis YopJ inhibits innate immune signaling.

Authors:  Nicholas Paquette; Joseph Conlon; Charles Sweet; Florentina Rus; Lindsay Wilson; Andrea Pereira; Charles V Rosadini; Nadege Goutagny; Alexander N R Weber; William S Lane; Scott A Shaffer; Stephanie Maniatis; Katherine A Fitzgerald; Lynda Stuart; Neal Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-16       Impact factor: 11.205

6.  Functional characterization of two type III secretion systems of Vibrio parahaemolyticus.

Authors:  Kwon-Sam Park; Takahiro Ono; Mitsuhiro Rokuda; Myoung-Ho Jang; Kazuhisa Okada; Tetsuya Iida; Takeshi Honda
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

7.  Adaptive and inflammatory immune responses in patients infected with strains of Vibrio parahaemolyticus.

Authors:  Firdausi Qadri; Muhammad Shamsul Alam; Mitsuaki Nishibuchi; Taufiqur Rahman; Nur Haque Alam; Jobayer Chisti; Seiichi Kondo; Junichi Sugiyama; Nurul Amin Bhuiyan; Minnie M Mathan; David A Sack; G Balakrish Nair
Journal:  J Infect Dis       Date:  2003-03-19       Impact factor: 5.226

8.  A series of wide-host-range low-copy-number vectors that allow direct screening for recombinants.

Authors:  V M Morales; A Bäckman; M Bagdasarian
Journal:  Gene       Date:  1991-01-02       Impact factor: 3.688

9.  Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB activation.

Authors:  Micah Luftig; Teruhito Yasui; Vishal Soni; Myung-Soo Kang; Nils Jacobson; Ellen Cahir-McFarland; Brian Seed; Elliott Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-22       Impact factor: 11.205

10.  Delivery of epitopes by the Salmonella type III secretion system for vaccine development.

Authors:  H Rüssmann; H Shams; F Poblete; Y Fu; J E Galán; R O Donis
Journal:  Science       Date:  1998-07-24       Impact factor: 47.728

View more
  35 in total

1.  Type 3 Secretion System Island Encoded Proteins Required for Colonization by Non-O1/non-O139 Serogroup Vibrio cholerae.

Authors:  Mudit Chaand; Kelly A Miller; Madeline K Sofia; Cory Schlesener; Jacob W A Weaver; Vibha Sood; Michelle Dziejman
Journal:  Infect Immun       Date:  2015-05-04       Impact factor: 3.441

Review 2.  Vibrio variations on a type three theme.

Authors:  Kelly A Miller; Katharine F Tomberlin; Michelle Dziejman
Journal:  Curr Opin Microbiol       Date:  2019-01-31       Impact factor: 7.934

3.  Characterization of V. cholerae T3SS-dependent cytotoxicity in cultured intestinal epithelial cells.

Authors:  Kelly A Miller; Mudit Chaand; Stacy Gregoire; Takeshi Yoshida; Lisa A Beck; Andrei I Ivanov; Michelle Dziejman
Journal:  Cell Microbiol       Date:  2016-07-22       Impact factor: 3.715

4.  Vibrio parahaemolyticus VopA Is a Potent Inhibitor of Cell Migration and Apoptosis in the Intestinal Epithelium of Drosophila melanogaster.

Authors:  Liping Luo; Jason D Matthews; Brian S Robinson; Rheinallt M Jones
Journal:  Infect Immun       Date:  2019-02-21       Impact factor: 3.441

5.  Parallel Evolution of Two Clades of an Atlantic-Endemic Pathogenic Lineage of Vibrio parahaemolyticus by Independent Acquisition of Related Pathogenicity Islands.

Authors:  Feng Xu; Narjol Gonzalez-Escalona; Kevin P Drees; Robert P Sebra; Vaughn S Cooper; Stephen H Jones; Cheryl A Whistler
Journal:  Appl Environ Microbiol       Date:  2017-08-31       Impact factor: 4.792

6.  Genetic analysis of Vibrio parahaemolyticus intestinal colonization.

Authors:  Troy P Hubbard; Michael C Chao; Sören Abel; Carlos J Blondel; Pia Abel Zur Wiesch; Xiaohui Zhou; Brigid M Davis; Matthew K Waldor
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-16       Impact factor: 11.205

7.  The Vibrio parahaemolyticus effector VopC mediates Cdc42-dependent invasion of cultured cells but is not required for pathogenicity in an animal model of infection.

Authors:  Ryu Okada; Xiaohui Zhou; Hirotaka Hiyoshi; Shigeaki Matsuda; Xiang Chen; Yukihiro Akeda; Takashige Kashimoto; Brigid M Davis; Tetsuya Iida; Matthew K Waldor; Toshio Kodama
Journal:  Cell Microbiol       Date:  2014-01-08       Impact factor: 3.715

8.  Structural and regulatory mutations in Vibrio parahaemolyticus type III secretion systems display variable effects on virulence.

Authors:  Thomas Calder; Marcela de Souza Santos; Victoria Attah; John Klimko; Jessie Fernandez; Dor Salomon; Anne-Marie Krachler; Kim Orth
Journal:  FEMS Microbiol Lett       Date:  2014-10-31       Impact factor: 2.742

9.  Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death.

Authors:  Pontus Orning; Dan Weng; Kristian Starheim; Dmitry Ratner; Zachary Best; Bettina Lee; Alexandria Brooks; Shiyu Xia; Hao Wu; Michelle A Kelliher; Scott B Berger; Peter J Gough; John Bertin; Megan M Proulx; Jon D Goguen; Nobuhiko Kayagaki; Katherine A Fitzgerald; Egil Lien
Journal:  Science       Date:  2018-10-25       Impact factor: 47.728

10.  Infant Rabbit Model for Diarrheal Diseases.

Authors:  Sören Abel; Matthew K Waldor
Journal:  Curr Protoc Microbiol       Date:  2015-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.